Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 4/20 | 0.66 |
| ▸ | TERT | O14746 | 2/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632043 | 1.00 | DTYMK (0.66) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL16983788 | 1.00 | DTYMK (0.66) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL29401735 | 0.96 | DTYMK (0.65) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL30301232 | 0.96 | DTYMK (0.65) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL29774178 | 0.96 | TERT (0.62) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL29359812 | 0.96 | TERT (0.62) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL29503590 | 0.96 | TERT (0.62) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL29923029 | 0.96 | TERT (0.62) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL15127423 | 0.96 | TERT (0.62) | DTYMKTERTF2RNASELP2RY2 | |
| SCHEMBL29429631 | 0.96 | TERT (0.62) | DTYMKTERTF2RNASELP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315537-B2 | Multiple orthogonal labelling of oligonucleotides | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20150218203-A1 | MULTIPLE ORTHOGONAL LABELLING OF OLIGONUCLEOTIDES | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218203-A1 | MULTIPLE ORTHOGONAL LABELLING OF OLIGONUCLEOTIDES | RTCB, ADAR, POLN | DTYMK 25/4885TERT 808/4885F2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.